{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.00"}]}],"title":"Highest % of CD8 cells Pre-vaccine"},{"categories":[{"measurements":[{"groupId":"OG000","value":"2.69"}]}],"title":"Best Response % of CD8 cells Day +30"}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"Best CD8+ response against CRM197 at day +30 after transplant, utilizing flow cytometry for interferon-γ (IFN-gamma). Peripheral blood mononuclear cells were stained with cell trace violet then incubated with CRM197 or vehicle control. Cells were then harvested and stained for flow cytometry. Highest percentage increase of CD8 cells from pre-vaccine to Day + 30.","groups":[{"description":"Pneumococcal conjugate vaccine (PCV 13), 0.5ml, 3 to 30 days prior to transplant and then again at 7-10 and 21-24 days after transplant.","id":"OG000","title":"Experimental: PCV 13"}],"paramType":"NUMBER","populationDescription":"All evaluable participants.","reportingStatus":"POSTED","timeFrame":"30 Days Post Vaccine","title":"CD8+CTV-IFN-gamma+, Best Response Against Vaccine (CRM 197)","type":"SECONDARY","unitOfMeasure":"percentage of CD8 cells"}